HK1246183A1 - Hpv疫苗 - Google Patents

Hpv疫苗

Info

Publication number
HK1246183A1
HK1246183A1 HK18105733.1A HK18105733A HK1246183A1 HK 1246183 A1 HK1246183 A1 HK 1246183A1 HK 18105733 A HK18105733 A HK 18105733A HK 1246183 A1 HK1246183 A1 HK 1246183A1
Authority
HK
Hong Kong
Prior art keywords
hpv vaccines
hpv
vaccines
Prior art date
Application number
HK18105733.1A
Other languages
English (en)
Inventor
奧爾林格 克勞斯
莫納思 湯瑪斯
莉亞 安德斯
施密特 莎拉
貝爾卡 耳舒拉
史溫丁格 邁克爾
沃森 伊莉莎白
基埃弗曼 貝蒂娜
辛特拉姆斯科格勒 朱麗亞
富爾曼 格哈德
埃斯珀克 安德列亞斯
科恩 凱薩琳
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of HK1246183A1 publication Critical patent/HK1246183A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK18105733.1A 2015-06-10 2018-05-03 Hpv疫苗 HK1246183A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562173805P 2015-06-10 2015-06-10
US201562254410P 2015-11-12 2015-11-12
US201662331158P 2016-05-03 2016-05-03
PCT/EP2016/063182 WO2016198531A2 (en) 2015-06-10 2016-06-09 Hpv vaccines

Publications (1)

Publication Number Publication Date
HK1246183A1 true HK1246183A1 (zh) 2018-09-07

Family

ID=56137292

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105733.1A HK1246183A1 (zh) 2015-06-10 2018-05-03 Hpv疫苗

Country Status (8)

Country Link
US (3) US10669315B2 (zh)
EP (1) EP3307308A2 (zh)
JP (2) JP7098330B2 (zh)
CN (2) CN115197965A (zh)
AU (2) AU2016274655B2 (zh)
CA (1) CA2987155A1 (zh)
HK (1) HK1246183A1 (zh)
WO (1) WO2016198531A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186978A1 (en) 2007-12-27 2023-05-31 Universität Zürich Replication-defective arenavirus vectors
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
JP7098330B2 (ja) 2015-06-10 2022-07-11 ホオキパ バイオテック ジーエムビーエイチ Ｈｐｖワクチン
CA3002819A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
AU2016348675B2 (en) 2015-11-04 2022-11-17 Hookipa Biotech Gmbh Vaccines against Hepatitis B virus
PL3373959T3 (pl) 2015-11-12 2022-10-24 Hookipa Biotech Gmbh Cząstki arenawirusa jako szczepionki przeciwrakowe
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018185307A1 (en) * 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
CN111212914A (zh) * 2017-07-14 2020-05-29 昂克诺斯公司 包封的多核苷酸和使用方法
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN108424925A (zh) * 2018-03-07 2018-08-21 江苏润洁生物科技有限公司 一种治疗性hpv核酸疫苗
WO2020102285A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
JP2022509221A (ja) * 2018-11-28 2022-01-20 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
CA3177949A1 (en) * 2020-05-14 2021-11-18 Stephanie RAMOS Vaccines for recurrent respiratory papillomatosis and methods of using the same
KR20230046278A (ko) 2020-05-29 2023-04-05 후키파 바이오테크 게엠베하 아레나바이러스 벡터를 이용한 암 치료 전략
IL305965A (en) 2021-03-23 2023-11-01 Hookipa Biotech Gmbh ARENAVIRUSES USED IN PROSTATE CANCER TREATMENTS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6869779B1 (en) * 1998-08-27 2005-03-22 Fuso Pharmaceutical Industries, Ltd. Nucleic acid sequence for potentiating the expression of useful gene and method therefor
DE122008000061I1 (de) * 1999-04-06 2009-02-12 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
ES2391451T3 (es) * 2002-10-03 2012-11-26 Wyeth Holdings Corporation Péptidos de fusión que comprenden los polipéptidos E7 y E6 de virus del papiloma humano y composiciones inmunogénicas de los mismos
MX2007006366A (es) * 2004-11-30 2008-03-10 Aeras Global Tb Vaccine Found Cepas empacadoras bacteriales utiles para la generacion y produccion de nucleocapsides de acido ribonucleico recombinante de doble cadena y usos de los mismos.
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP4186978A1 (en) 2007-12-27 2023-05-31 Universität Zürich Replication-defective arenavirus vectors
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
ES2646590T3 (es) 2012-01-24 2017-12-14 Sanford Health Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
WO2016048949A1 (en) 2014-09-22 2016-03-31 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
JP7098330B2 (ja) 2015-06-10 2022-07-11 ホオキパ バイオテック ジーエムビーエイチ Ｈｐｖワクチン
EP3365005A1 (en) 2015-10-23 2018-08-29 Institut Pasteur Recombinant mopeia virus and vaccine platform
AU2016348675B2 (en) 2015-11-04 2022-11-17 Hookipa Biotech Gmbh Vaccines against Hepatitis B virus
PL3373959T3 (pl) 2015-11-12 2022-10-24 Hookipa Biotech Gmbh Cząstki arenawirusa jako szczepionki przeciwrakowe
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
BR112018073794A2 (pt) 2016-05-18 2019-02-26 Hookipa Biotech Gmbh segmento genômico, cdna, vetor, célula hospedeira, partícula, método de produção de um segmento genômico, método de geração da partícula, vacina, composição farmacêutica
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
JP2023500928A (ja) 2019-11-07 2023-01-11 ユニベルシタト バーゼル ベクターとしてのアレナウイルス
KR20230046278A (ko) 2020-05-29 2023-04-05 후키파 바이오테크 게엠베하 아레나바이러스 벡터를 이용한 암 치료 전략

Also Published As

Publication number Publication date
AU2021232660A1 (en) 2021-10-07
CN107921117A (zh) 2018-04-17
AU2016274655B2 (en) 2021-06-17
CN107921117B (zh) 2022-06-07
WO2016198531A2 (en) 2016-12-15
US11407790B2 (en) 2022-08-09
JP2018518172A (ja) 2018-07-12
AU2016274655A1 (en) 2017-12-21
US20210024584A1 (en) 2021-01-28
US20230086859A1 (en) 2023-03-23
CA2987155A1 (en) 2016-12-15
US20180179257A1 (en) 2018-06-28
CN115197965A (zh) 2022-10-18
JP7098330B2 (ja) 2022-07-11
JP2022160401A (ja) 2022-10-19
WO2016198531A3 (en) 2017-01-19
US10669315B2 (en) 2020-06-02
EP3307308A2 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
HK1246183A1 (zh) Hpv疫苗
HRP20190442T1 (hr) Kapsid
ZA201904717B (en) Therapeutic hpv18 vaccines
HRP20181895T1 (hr) Terapijska hpv16 cjepiva
GB201410971D0 (en) Vaccine
GB201518684D0 (en) Vaccine
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
GB201406608D0 (en) Virus
GB201522132D0 (en) Vaccine
GB201419572D0 (en) Virus
SG11202001244SA (en) Hpv vaccine
GB201616904D0 (en) Vaccine
GB201608821D0 (en) Vaccines
HUE053284T2 (hu) Vakcina
GB201417214D0 (en) Vaccine
GB201614387D0 (en) Improved vaccines
GB201603029D0 (en) Vaccine
GB201518917D0 (en) Vaccination
GB201522013D0 (en) Virus
GB201516936D0 (en) Virus
GB201503266D0 (en) Vaccination
GB201507419D0 (en) Virus
GB201406628D0 (en) Vaccine
GB201406470D0 (en) Virus
GB201403582D0 (en) Virus